Dr Agarwals Healthcare IPO Details
The key details of Dr Agarwals Healthcare’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹3,027.26 Cr |
| Price Range | ₹382 - ₹402 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 35 |
| Investment (cut-off price) | ₹14,070 |
| Pre IPO Promotor Holding | 37.72% |
| Post IPO Promotor Holding | 32.5% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Dr Agarwals Healthcare IPO Timelines
The IPO process for Dr Agarwals Healthcare includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
29/01/2025
Start Date31/01/2025
End Date03/02/2025
Refund Initiation03/02/2025
Credit of Shares to Demat Ac04/02/2025
Listing DateDr Agarwals Healthcare IPO Lot Size
The Dr Agarwals Healthcare IPO has a fixed lot size of 35 shares, at an upper price band of ₹402 per share, requiring ₹14,070 per lot for retail investors. Retail investors can apply for a maximum of 490 shares worth ₹196,980. For Small HNI (S-HNI), the minimum application starts at 525 shares (₹211,050) up to 2,485 shares (₹998,970), while Big HNI (B-HNI) requires a minimum of 2,520 shares amounting to ₹1,013,040.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 35 | ₹14,070 |
| Retail Maximum | 14 | 490 | ₹1,96,980 |
| S-HNI Minimum | 15 | 525 | ₹2,11,050 |
| S-HNI Maximum | 71 | 2485 | ₹9,98,970 |
| B-HNI Minimum | 72 | 2520 | ₹10,13,040 |
Dr Agarwals Healthcare IPO Subscription Status
The subscription status for Dr Agarwals Healthcare IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 4.41x | 0.39x | 0.42x | 0.26x | 1.49x |
IPO Performance on Listing Day
On the listing day (February 4, 2025), Dr Agarwals Healthcare made a flat debut on the stock exchange. The stock opened at ₹402, exactly at its issue price. During the trading session, while the stock managed to touch a high of ₹412.90, it also faced some selling pressure that pulled it down to ₹370.20. The shares closed at ₹401.65, almost at par with the issue price, recording a marginal loss of 0.1%, suggesting a balanced market response to this healthcare chain.
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹402.00 | ₹401.65 | ₹412.90 | ₹370.20 |
Dr Agarwals Healthcare IPO Company Financials
Dr Agarwals Healthcare reports robust performance in FY2024 with Total Income of ₹1,376.45 crores, managing expenses at ₹1,235.88 crores, and achieving a strong PAT (Profit After Tax) of ₹95.05 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2022 | ₹713.78 | ₹657.02 | ₹43.16 |
| FY 2023 | ₹1,031.49 | ₹947.90 | ₹103.23 |
| FY 2024 | ₹1,376.45 | ₹1,235.88 | ₹95.05 |
| FY 2025 (6 M) | ₹837.94 | ₹777.59 | ₹39.56 |
About Company
Dr. Agarwal’s Health Care Limited, founded in 2010, is a leading provider of eye care services, offering a broad range of treatments such as cataract and refractive surgeries, consultations, diagnoses, and non-surgical therapies. The company also sells optical products, contact lenses, accessories, and eye care-related pharmaceuticals. By September 30, 2024, the company employed 737 doctors and served over 2.13 million patients, performing 220,523 surgeries. In the six-month period leading up to this date, 1.15 million patients were treated, with 140,787 surgeries conducted.
The company operates a vast network of eye care facilities across India, with 28 tertiary hubs, including three Centers of Excellence (COEs), and 165 spokes comprising primary and secondary facilities. As of September 30, 2024, Dr. Agarwal’s Health Care Limited had a presence in 117 cities, spanning 14 states and four union territories, through 193 locations. The services offered include various cataract surgical treatments, refractive surgeries like LASIK and SMILE, as well as specialized procedures for conditions such as glaucoma, corneal issues, and retinal diseases.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2010 | Healthcare | Anosh Agarwal |
Know Before Investing
Dr Agarwals Healthcare IPO Strengths
- Dr Agarwal’s Healthcare commands a 25% share of India’s eye care market, positioning it as a leading player in the industry.
- The company provides a wide range of eye care services, including cataract surgeries, refractive surgeries, and optical products, catering to diverse patient needs.
- With 165 centers in India and 15 internationally, the company has a well-established network that supports growth and accessibility.
- The IPO will raise ₹300 crores, with ₹195 crores allocated for debt repayment, enhancing financial stability and reducing interest burdens.
- Backed by prominent investors like Temasek Holdings and TPG, Dr Agarwal’s has strong financial backing and credibility.
- The operational model allows for scalable and efficient service delivery across multiple locations, enhancing patient access to care.
Dr Agarwals Healthcare IPO Risks
- A significant portion of revenue is generated from surgeries, making the company vulnerable to fluctuations in patient footfall and economic conditions.
- The eye care industry is highly competitive, which may pressure profit margins and limit growth opportunities for Dr Agarwal’s Healthcare.
- The company must adhere to stringent healthcare regulations; non-compliance could result in legal penalties and operational disruptions.
- Retaining skilled medical professionals is crucial; high turnover rates could impact service quality and patient satisfaction.
- The performance of the healthcare sector can be sensitive to economic downturns, potentially affecting patient spending on elective procedures.
- Any negative publicity or service quality issues could harm the company’s reputation, leading to a decline in patient trust and business.
- A significant concentration of operations in certain regions may expose the company to local economic fluctuations and regulatory changes.
- Inefficiencies in service delivery or disruptions in operations could adversely affect patient care and overall business performance.
Swot Analysis for Dr Agarwals Healthcare IPO
Strengths
Established brand, Extensive network, Specialized medical expertise
Weaknesses
High operational costs, Limited service diversification, Regional market dependence
Opportunities
Growing healthcare demand, Expansion into new regions, Telemedicine growth
Threats
Intense competition, Regulatory changes, Economic downturn affecting patient volume
Company Details
Dr. Agarwal’s Health Care Limited
1 st Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Near Asan Memorial School, Chennai 600 006
Phone: +91 44 4378 7777
Email: secretarial@dragarwal.com
Website: https://dragarwals.co.in/
IPO Registar Details
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: ahcl.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
FAQs
The key objectives of Dr Agarwals Healthcare IPO are:
- Repayment/prepayment, in part or full, of certain of the borrowings and
- General corporate purposes and unidentified inorganic acquisition.
Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Pvt Ltd, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited are the book-running lead managers for the Dr Agarwals Healthcare IPO.